8-K: 23andMe Faces Nasdaq Delisting Following Bankruptcy Filing

23andMe Holding Co. is set to be delisted from the Nasdaq Stock Market after filing for Chapter 11 bankruptcy.

Summary

• 23andMe Holding Co. filed for Chapter 11 bankruptcy on March 23, 2025.
• On March 24, 2025, Nasdaq notified the company that its securities would be delisted due to the bankruptcy filing.
• Trading of 23andMe's Class A common stock will be suspended on March 31, 2025, unless the company requests a hearing, which it does not intend to do.
• The company expects its common stock to be quoted on the OTC Pink Market after delisting, but there is no guarantee of continued trading.
• Trading in 23andMe's securities during the bankruptcy proceedings is considered highly speculative and poses substantial risks.
• Court filings related to the Chapter 11 cases can be found on a website maintained by Kroll, the company's claims agent.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the bankruptcy filing and subsequent delisting notice. This indicates significant financial distress and uncertainty for the company's future.

Negatives

• 23andMe is facing delisting from the Nasdaq Stock Market.
• The company has filed for Chapter 11 bankruptcy.
• Trading in the company's securities is highly speculative and risky.

Risks

• The Chapter 11 cases pose risks to the company and its stakeholders.
• The company's ability to obtain court approval for motions is uncertain.
• The outcome of the Chapter 11 cases is uncertain.
• The trading price of the common stock is volatile.
• There is no guarantee that the common stock will continue to trade on the OTC Pink Market.

Future Outlook

The company anticipates that its common stock will be quoted on the OTC Pink Market upon delisting from The Nasdaq Stock Market, but there is no assurance that the Common Stock will commence or continue to trade on this market.

Industry Context

This announcement reflects the financial difficulties faced by 23andMe, impacting its listing status and potentially affecting investor confidence in the personal genetics and biotechnology sector.

Legal Proceedings

• The company and its subsidiaries have filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code.

Stakeholder Impact

• Shareholders face substantial risks due to the speculative nature of trading during bankruptcy.
• Employees face uncertainty regarding the company's future.
• Customers may be concerned about the continuity of services.
• Creditors face uncertainty regarding the recovery of their claims.

Next Steps

• The company expects its Common Stock will be delisted from The Nasdaq Stock Market.
• The Company anticipates that, upon the delisting from The Nasdaq Stock Market, the Common Stock will be quoted on the OTC Pink Market.

Key Dates

Keywords

bankruptcy, delisting, Nasdaq, Chapter 11, 23andMe, securities, common stock, OTC Pink Market